Absci
ABSI

$4.48

3.88%

Market Cap: 507M

About: Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.

Employees: 156

Industrials Commercial Physical & Biological Research

0

Funds holding %

of 6,702 funds

0

Analysts bullish %

of 8 analysts

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

799% more call options, than puts

Call options by funds: $8.33M | Put options by funds: $926K

767% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 6

142% more capital invested

Capital invested by funds: $142M [Q4 2023] → $344M (+$202M) [Q1 2024]

114% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 14

69% more funds holding

Funds holding: 67 [Q4 2023] → 113 (+46) [Q1 2024]

17.33% more ownership

Funds ownership: 36.3% [Q4 2023] → 53.63% (+17.33%) [Q1 2024]

See Fund Rankings

Research analyst outlook

8 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target

$6

34%

upside

Avg. target

$8.25

84%

upside

High target

$13

190%

upside

8 analyst ratings

8 positive

100%

0 neutral

0%

0 negative

0%

Keybanc Scott Schoenhaus	34%upside $6	Overweight Maintained	11 Jul 2024
Morgan Stanley Vikram Purohit	56%upside $7	Overweight Initiated	3 Jul 2024
HC Wainwright & Co. Swayampakula Ramakanth	56%upside $7	Buy Reiterated	15 May 2024
Truist Securities Robyn Karnauskas	101%upside $9	Buy Maintained	26 Mar 2024
HC Wainwright & Co. Swayampakula Ramakanth	56%upside $7	Buy Reiterated	22 Mar 2024

See Analyst Rankings

Financial journalist opinion

Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024

VANCOUVER, Wash. and NEW YORK, July 10, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the second quarter after market close on Wednesday, August 14, 2024.

Absci to Report Business Updates and Second Quarter 2024 Financial and Operating Results on August 14, 2024

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

VANCOUVER, Wash. and NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced that on July 1, 2024, the company granted a non-statutory stock option to purchase an aggregate of 613,000 shares of its common stock to Ms. Shelby Walker in connection with her employment as Absci's Chief Legal Officer. The inducement grant was previously approved by Absci's Board of Directors pursuant to Absci's 2023 Inducement Plan (the “Inducement Plan”), and is being made as an inducement material to Ms. Walker's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

Absci Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

VANCOUVER, Wash. and NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL.

Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs

It's no secret that artificial intelligence ( AI ) promises to transform every industry and sector, pharma included. But how do those companies plan to leverage AI, and what will it do for their stocks?

7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs

Absci Corporation (ABSI) Q1 2024 Earnings Call Transcript

Absci Corporation. (NASDAQ:ABSI ) Q1 2024 Earnings Conference Call May 14, 2024 8:30 AM ET Company Participants Alex Khan – Vice President, Finance and Investor Relations Sean McClain – Founder and Chief Executive Officer Zach Jonasson – Chief Financial Officer and Chief Business Officer Christian Stegmann – SVP of Drug Creation Conference Call Participants Kripa Devarakonda – Truist Securities George Farmer – Scotia Bank Jacqueline Kisa – TD Cowen Steve Dechert - KeyBanc Capital Markets Li Chen – H.C.

Absci Corporation (ABSI) Q1 2024 Earnings Call Transcript

Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results

Initiated IND-enabling studies for ABS-101 in February Continuing to advance ABS-201 and ABS-301 through preclinical studies VANCOUVER, Wash. and NEW YORK, May 14, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended March 31, 2024.

Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results

Zacks Investment Research

Absci (ABSI) to Report Q1 Earnings: Here's What to Expect

The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results.

Absci (ABSI) to Report Q1 Earnings: Here's What to Expect

Zacks Investment Research

Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?

Absci Corporation (ABSI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Absci Corporation (ABSI) Moves 16.8% Higher: Will This Strength Last?

Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results

Initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody Entered into collaboration with AstraZeneca for up to $247M in deal value, plus royalties Strengthened balance sheet raising approximately $86M in gross proceeds through underwritten common stock offering VANCOUVER, Wash. and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the fourth quarter and year ended December 31, 2023.

Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results

Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

VANCOUVER, Wash., March 01, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI) (“Absci”), a data-first generative AI drug creation company, today announced the closing of its underwritten public offering of 19,205,000 shares of its common stock at a public offering price of $4.50 per share, before deducting underwriting discounts and commissions. The shares of common stock include 2,505,000 shares pursuant to the option granted by Absci to the underwriters, which was exercised in full. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $86.4 million. All of the shares in the offering were sold by Absci.

Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters' Option to Purchase Additional Shares

See News Rankings